Potassium voltage-gated channel subfamily Q member family (KCNQ family)

The KCNQ family, also known as the Kv7 family, comprises five members (KCNQ1-KCNQ5) of voltage-gated potassium channels that play critical roles in regulating cellular excitability across various tissues. KCNQ1 is primarily expressed in the heart and is essential for cardiac repolarization, while KCNQ2 through KCNQ5 are predominantly found in the nervous system, where they generate the M-current—a slow-activating and non-inactivating potassium current that limits repetitive neuronal firing. Mutations in these channels are linked to severe disorders, including neonatal epilepsy, Long QT syndrome, and progressive hearing loss. Pharmacologically, KCNQ activators like Retigabine have been utilized as anticonvulsants by stabilizing the resting membrane potential, though their use is often limited by off-target effects and specific safety concerns such as tissue pigmentation. Current drug development focuses on subtype-selective modulators to treat epilepsy, neuropathic pain, and mood disorders while minimizing systemic toxicity.

Other names

Kv7 familyKQT-like subfamilyVoltage-gated potassium channel subfamily QM-channel

Positive allosteric modulation (channel opening) to stabilize resting membrane potential; Pore blocking (channel inhibition) to increase excitability or secretion.